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Summary
Hyperhomocysteinemia is a risk factor for venous thrombosis,
but the underlying mechanism is unclear. If the thiol-group of
homocysteine interferes with components of the clotting sys-
tem,we expect that high cysteine will be also a risk factor for ve-
nous thrombosis. If high homocysteine reflects a disturbed
methyl-group donation by S-adenosylmethionine, we expect
that low methionine will be a risk factor for thrombosis. We
performed a case-control study in 185 patients with recurrent
venous thrombosis and in 500 control subjects.
We determined methionine, homocysteine, cysteine and as-
sessed the associated thrombotic risk. Low fasting methionine
was associated with an increased risk on recurrent venous
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thrombosis [OR
bottom vs. top quartile
= 3.3 (95%CI 1.9–5.7)]. Low
methionine remained a risk factor [OR
bottom vs. top quartile
= 3.5
(95%CI 2.0–6.0)] after adjusting for homocysteine and cysteine,
whereas the thrombotic risk for homocysteine was lost [OR=
1.0 (95%CI 0.6–1.9)] after adjustment. Cysteine yielded a hig-
hest odds ratio of 2.1
top vs. bottom quartile
(95%CI 1.0–4.0) after ad-
justment. In conclusion, we found that low fasting methionine is
a risk factor for recurrent venous thrombosis.This risk associ-
ation was stronger for methionine than for homocysteine or
cysteine.This supports the hypothesis that impaired methylation
may be involved in the pathogenesis of venous thrombosis.
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Introduction
Hyperhomocysteinemia is associated with the occurrence of ar-
terial vascular disease and venous thrombosis (1–2). Several
mechanisms have been suggested to explain the relationship be-
tween homocysteine and thrombotic disease. One hypothesis is
that the thiol-group of homocysteine interferes with components
of the clotting system (3–6). If this is true, it could be expected
that other thiol-containing compounds, like cysteine, which has
a close structural similarity to homocysteine, also have thrombo-
genic properties. Cysteine could therefore also be a risk factor
for thrombosis, whereas methionine, which does not have a thiol-
group, would not be expected to be associated with an increased
risk of thrombosis.
Another hypothesis focuses on a main purpose of the homo-
cysteine metabolism, namely the donation of a methyl group by
S-adenosylmethionine (AdoMet) (Fig. 1), which is used in many
cellular methyltransferase processes, including methylation of
DNA, RNA, lipids and proteins. A shortage of methionine lead-
ing to low AdoMet levels could influence several of the men-
tioned methylation processes, for instance DNA methylation (7),
which in turn could contribute to the pathological cascade lead-
ing to venous thrombosis. If this hypothesis is true, hyperhomo-
cysteinemia is merely a marker of an impaired metabolism of
methyl groups, and one could expect that other metabolites that
reflect this process, for instance low methionine, could also be
risk factors for thrombosis. Hypercysteinemia, on the other
hand, does not reflect this process, so it would not be expected to
be a risk factor for thrombosis.
In order to determine which of the above hypotheses is more
likely, we performed a case-control study and investigated the
risk of recurrent venous thrombosis for metabolites and vitamins
of the homocysteine metabolism, i.e. methionine, homocysteine,
cysteine, betaine, plasma folate and red blood cell folate. We also
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investigated whether risk associations were modified by com-
pounds of the homocysteine metabolism or by the factor V
Leiden or prothrombin 20210G>A mutation.
Methods
Subjects
For the current study, we used samples of a previously published
case-control study (8, 9). In the Netherlands, virtually all pa-
tients with a history of venous thrombosis are registered at an
anticoagulant clinic. We approached 473 patients who had had
two or more episodes of venous thrombosis and invited them to
take part in this study. Of those 473 patients, 185 patients (39%)
agreed to participate.
Through a general practice inThe Hague, 2,812 possible con-
trol subjects between 20 and 90 years of age were invited by letter
to participate in a study on risk factors for cardiovascular dis-
ease. Five hundred ninety-one (21%) responded positively and
subsequently received additional information by mail, after
which 532 subjects agreed to participate. Of those 532 subjects,
10 as yet refused because of psychiatric problems (1), myoc-
ardial infarction (1), back pain (1) and undefined reasons (7). Of
the 521 subjects left, 18 did not show up for blood sample collec-
tion, one subject refused venipuncture and for two subjects veni-
puncture was not possible. This left 500 control subjects who
participated in the study. The only exclusion criterion was preg-
nancy.
The study was approved by the ethics committee of the
Leyenburg Hospital, and informed consent was obtained from
all participants.
Figure 1: Homocysteine
metabolism. AdoMet =
S-adenosylmethionine, AdoHcy
= S-adenosylhomocysteine,
CBS = cystathionine-β- syn-
thase, C = γ-cystathionase, MS
= methionine synthase,
MTHFR = 5,10-methylenetet-
rahydrofolatereductase, THF =
tetrahydrofolate, BHMT = be-
taine-homocysteine methyl-
transferase.
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Methods
Because amino acid levels are influenced by diet, blood samples
of all 185 patients and 500 control subjects were collected after
overnight fasting. The samples were obtained from the antecubi-
tal vein in 4.5-ml EDTA vacuum glass tubes. They were used to
determine the plasma concentrations of methionine, homocys-
teine, cysteine, folate, vitamin B12, vitamin B6 and vitamin B2
(riboflavin) and for detecting the methylenetetrahydrofolatere-
ductase (MTHFR) 677C>T, factor V Leiden (1691G>A) and
prothrombin 20210G>A polymorphism.
The blood samples for plasma determinations were immedi-
ately placed on ice and centrifuged at 3,500 g for 5 min within
two hours. The plasma was separated and stored at –20 ºC until
analysis. Total cysteine and total homocysteine concentrations in
plasma were measured by an automated high-performance
liquid chromatography method with fluorescent detection, es-
sentially according to the method by Fiskerstrand et al. (10)
which was slightly modified (11). The inter- and intra-run coef-
ficient of variation was less than 6.5% for homocysteine concen-
trations (11) and less than 5% for cysteine levels (12). Concen-
trations of methionine in plasma were determined by a modifi-
cation of a method based on normal phase liquid chroma-
tography- tandem mass spectrometry (13). Because methionine
is oxidised during storage, we calculated the total methionine
concentration as the sum of methionine and methionine sulf-
oxide. The inter- and intra-run coefficient of variation for me-
thionine levels was about 5%. Folate and vitamin B12 concen-
trations were measured in plasma samples stored at –70 ºC with
the Dualcount SPNB (solid phase no boil) Radioassay (Diag-
nostic Product Corporation, Los Angeles, CA, USA). Vitamin
B6 (sum of pyridoxal 5’-phosphate and pyridoxal) and vitamin
B2 were measured with liquid chromatography – tandem mass
spectometry (14). MTHFR 677C>T, factor V Leiden and pro-
thrombin 20210G>A genotyping was performed as previously
described (9).
Statistical analysis
Because we used data of a previously performed case-control
study we calculated the “smallest detectable relative risk” (alpha
0.05 and power 0.8), which was 1.67 for an odds ratio (OR) above
1. Group characteristics are given as medians and ranges.
To investigate a possible dose-response relationship, we used
the following logistic regression models: First, a univariate
analysis was carried out for each of the variables methionine,
homocysteine and cysteine. Second, each analysis was repeated
with the additional covariables sex and age. Third, the variables
methionine, homocysteine, cysteine, age and sex were all in-
cluded and evaluated in one multivariate model. In an additional
analysis, second order terms were included in the models to
check for possible non-linearity and interactions (effect modifi-
cation). We calculated 95% confidence intervals (95%CI) for the
OR.
For easy interpretation of the results, the OR could be inter-
preted as the relative risk to develop recurrent venous thrombo-
sis for quartiles of the continuous variables. We used either the
top quartile or the bottom quartile as a reference group. Because
we did a case-control study in patients with recurrent venous
thrombosis, the OR might be higher than expected for first-time
venous thrombosis.
To evaluate a possible effect modification we calculated the
relative risks for combinations of quartiles. For the combination
of methionine and homocysteine, we used subjects with low
homocysteine and high methionine as a reference group. For the
combination of methionine with cysteine, we used subjects with
low cysteine and high methionine as a reference group.
Furthermore, we investigated the joint effects for methionine
in combination with the factor V Leiden, prothrombin
20210G>A and MTHFR 677C>T mutation. When the number
of homozygote genotype variants was too small, as in the case of
factor V Leiden, heterozygotes and homozygotes were taken to-
gether. We used subjects that had high methionine levels (top
quartile) and wildtype factor V Leiden, prothrombin 20210G>A
or wildtype MTHFR 677 C>T as a reference group.
We also investigated the risk of recurrent venous thrombosis
associated with methionine concentrations below the median for
subgroups of the MTHFR 677C>T mutation. Subjects with a
methionine concentration above the median were the reference
group.
Results
Baseline characteristics are shown in Figure 1. There was no sig-
nificant correlation in control subjects between methionine and
homocysteine concentration (r= –0.02; p=0.72) and a weak cor-
relation between methionine and cysteine concentration (r=
–0.10; p=0.03). Homocysteine and cysteine levels were moder-
ately correlated (r=0.329; p<0.001).
Univariate analysis
We found methionine to be associated with a gradual increased
risk (P for trend= <0.001) of recurrent venous thrombosis with
an age and sex-adjusted OR of 3.3 (95%CI 1.9–5.7) for a me-
thionine concentration below 20.6 µM (Table 1). The thrombotic
risk associated with homocysteine was also dose-dependent (P
for trend= 0.01), with a highest adjusted risk of 1.4 (95%CI
0.8–2.4) for the top quartile (Table 1). We also calculated the risk
of recurrent venous thrombosis for subjects with a homocysteine
concentration above the 90
th
percentile, which yielded an ad-
justed (age and sex) OR of 1.7 (95%CI 1.1 to 2.8), which is in
line with previously published results (8, 9). For cysteine the
dose response relationship was attenuated (P for trend= 0.3) after
adjusting for age and sex with a highest odds ratio of 1.9 (95%CI
1.0–3.4) for the top quartile.
Multivariate analysis
When the relative risks associated with quartiles of methionine,
homocysteine and cysteine levels were not only adjusted for age
and sex but also for each other, low methionine remained associ-
ated with an increased risk of venous thrombosis [OR=3.5
(95%CI 2.0–6.0)] whereas the thrombotic risk associated with
homocysteine levels was lost for every of the upper three quar-
tiles [OR=1.0 (95%CI 0.6–1.9)] (Table 2). Cysteine yielded a
highest OR of 2.1 (95%CI 1.0–4.0) for the top quartile.
Effect modification
We calculated the OR for quartiles of methionine levels in com-
bination with quartiles of homocysteine (Table 3) or cysteine
concentrations (data not shown). The risk on recurrent venous
thrombosis remained high in the bottom quartile of fasting me-
thionine concentrations independent of homocysteine (Table 3)
or cysteine (data not shown).
We repeated the analyses with adjustment for vitamin intake,
smoking and blood levels of plasma folate, vitamin B12, vitamin
B6 and vitamin B2. We found that low methionine is a risk fac-
tor for recurrent venous thrombosis independent of these vari-
ables (data not shown).
Next, we investigated a possible interaction between methion-
ine and factor V Leiden or prothrombin 20210G>A, i.e. well-es-
tablished genetic risk factors for venous thrombosis. The same
analysis was performed for the MTHFR 677C>T mutation. The
combination of low methionine concentration (bottom quartile)
and factor V Leiden yielded an adjusted (age and sex) OR of 15.9
(95%CI 5.5 to 45.9). In comparison, the OR for subjects with low
methionine levels and no factor V Leiden was 3.9 (95%CI 2.0 to
7.7) and it was 9.9 (95%CI 3.1 to 32.0) for subjects with factor V
Leiden and high methionine levels (top quartile). However, be-
cause of the wide confidence interval no conclusive interpre-
tations could be made about a possible biological interaction. No
clear interaction was found between low methionine and the pro-
thrombin 20210GA mutation or the MTHFR 677TT mutation.
Because the MTHFR 677TT genotype is a modest risk factor
for venous thrombosis and is associated with elevated homocys-
teine levels, we performed an analysis to investigate whether the
thrombotic risk associated with methionine levels below the
median differed according to MTHFR genotype. Median me-
thionine levels were similar in control subjects with the MTHFR
677TT genotype [23.6 µM (range 13.6 to 58.4)] and the MTHFR
677CC genotype [24.0 µM (range 16.7 to 37.6)].The highest risk
association for a methionine concentration below the median
was found in subjects with the MTHFR 677TT genotype, yield-
ing an odds ratio of 3.0 (95%CI 0.7–12.6). For the MTHFR
677CC group we found an OR of 2.0 (95%CI 1.1–3.5) for the
risk of recurrent venous thrombosis associated with methionine
levels below the median. However, because of the wide con-
fidence intervals no conclusive interpretations can be draw.
Discussion
The main finding in this study is that low fasting methionine le-
vels (< 20.6 µM) are associated with a 3.3-fold (95%CI 1.9–5.7)
increased risk of recurrent venous thrombosis. In all analyses,
whether multivariate or univariate, a decrease in methionine le-
vels was associated with an increased risk of venous thrombosis.
Furthermore, we found that methionine has a stronger risk as-
sociation with recurrent venous thrombosis than homocysteine
or cysteine. The thrombotic risk associated with methionine le-
Variable Cases (n=185) Controls (n=500) P-value
Sex (men) 094 (51%) 208 (42%) 0.03
Post-menopausal women 064 (35%) 138 (28%) <0.01
Time between 1st event and study (years) 017 (1−58) -
Time between last event and study (years) 007 (1−30) -
Smoking (yes/no) 061(33%) 167 (34%) 0.9
B-Vitamin use (yes/no) 023 (12%) 076 (15%) 0.9
Creatinine (µM) 081 (61–112) 074 (55–99) <0.01
Folate (nM) 013.5 (7.7–23.5) 012.7 (7.0–23.6) 0.2
Vitamin B12 (pM) 241 (118–466) 217 (125–389) 0.04
Vitamin B6 (nM) 025.8 (12.7–55.7) 027.6 (15.7–54.8) 0.03
Vitamin B2 (nM) 010.2 (4.9–37.1) 009.1 (4.0–25.9) 0.07
FactorV Leiden (MAF)†
– wildtype
– heterozygotes
– homozygotes
014.6%
124
044
003
003.3%
438
031
000
<0.01
Prothrombin G20210A (MAF)†
– wildtype
– heterozygotes
002.9%
010
162
001.6%
010
162
0.12
MTHFR C677T (MAF)†
– wildtype
– heterozygotes
– homozygotes
033.3%
075
094
014
029.1%
247
191
045
0.21
* Data are given as medians with 10th to 90th percentiles in parentheses for continous variables and as numbers with percentages in parentheses for categorial
variables, † MAF, minor allele frequency.
Age (year) 062 (42−79) 050 (34 to 69) <0.01
Table 1: Baseline char-
acteristics of patients with
recurrent venous
thrombosis cases and
control subjects*.
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vels below the median was highest in subjects with the MTHFR
677TT genotype. The combination of low methionine and factor
V Leiden yielded an OR of 15.9 (95%CI 5.5–45.9). However,
confidence intervals were too wide to make conclusive interpre-
tations about a possible biological interaction from the latter ob-
servation. Cysteine yielded a highest odds ratio of 2.1 (95%CI
1.0–4.0) for the top quartile after adjustment.
The mechanisms by which hyperhomocysteinemia may
cause thrombotic disease are poorly understood. Homocysteine
is a sulfur-containing amino acid that can only be formed from
methionine (Fig. 1). Methionine is a precursor of S-adenosyl-
methionine (AdoMet), which serves as a methyl donor in trans-
methylation reactions. Demethylation of AdoMet results in the
formation of S-adenosylhomocysteine (AdoHcy), which is hy-
drolyzed to homocysteine and adenosine. Homocysteine is de-
graded via the transsulfuration pathway or salvaged via re-
methylation to methionine (15). Homocysteine can be remethyl-
ated by methionine synthase for which 5-methyltetrahydrofolate
is a substrate and vitamin B12 is a cofactor. An alternative re-
methylation pathway is catalyzed by betaine-homocysteine
methyltransferase (BHMT), which uses betaine as a methyl-
donor.
The first hypothesis we investigated involves an impaired
methylation pathway resulting in a reduced availability of methyl
groups for methylation reactions, which may have a possible role
in the development of venous thrombosis (7). If this is true,
homocysteine is just a marker, and other metabolites that reflect
this process, for instance low methionine, could also be expected
to confer an increased thrombotic risk. The finding that low me-
thionine is associated with a three-fold increased risk of recur-
rent venous thrombosis and that it is a stronger risk factor than
high homocysteine or high cysteine, is in line with this hypothe-
sis.
The loss of thrombotic risk for homocysteine after adjust-
ment for methionine and cysteine levels and the finding that me-
thionine has a stronger risk association with recurrent venous
thrombosis is of interest and could suggest that methionine is a
better marker for risk assessment of recurrent venous thrombo-
sis. Quéré et al. (16) also found low methionine to be stronger as-
sociated with venous thrombosis than hyperhomocysteinemia in
Variables Cases Controls OR model1
(95%CI)
OR model2
(95%CI)
OR model3
(95%CI)
23.3–26.4 (µM) 46 124 1.8 (1.1–3.1) 1.8 (1.0–3.1) 1.9 (1.1–3.3)
> 26.4 (µM) 29 144 1.0
†
1.0
†
1.0
†
Plasma homocysteine P=0.01
‡
P=0.8
‡
<11.3 (µM) 30 141 1.0
†
1.0
†
1.0
†
11.3–13.4 (µM) 40 131 1.4 (0.8–2.4) 1.1 (0.7–2.0) 1.0 (0.6–1.8)
13.4–15.9 (µM) 49 122 1.9 (1.1–3.2) 1.2 (0.7–2.0) 1.0 (0.5–1.7)
>15.9 (µM) 66 106 2.9 (1.8–4.8) 1.4 (0.8–2.4) 1.0 (0.6–1.9)
Plasma cysteine P=0.3
‡
P=0.2
‡
< 198.4 (µM) 24 147 1.0
†
1.0
†
1.0
†
198.4–217.9 (µM) 42 129 2.0 (1.1–3.5) 1.5 (0.8–2.7) 1.6 (0.9–2.9)
217.9–238.1 (µM) 45 126 2.1 (1.3–3.8) 1.3 (0.7–2.3) 1.4 (0.7–2.5)
> 238.1 (µM) 74 097 4.7 (2.8–7.9) 1.9 (1.0–3.4) 2.1 (1.0–4.0)
* Adjusted for age and sex,
†
Reference category,
‡
P for trend.
Plasma methionine P<0.001
‡
P<0.001
‡
< 20.6 (µM) 62 108 2.9 (1.7–4.7) 3.3 (1.9–5.7) 3.5 (2.0–6.0)
20.6–23.3 (µM) 48 123 1.9 (1.2–3.3) 2.0 (1.2–3.5) 2.1 (1.2–3.6)
Plasma methionine (µM)
<20.6 20.6–23.3 23.2–26.4 >26.4
Plasma homocysteine
<11.3 (µM) 6.7 (1.7–27.3) 4.2 (1.0–17.8) 3.0 (0.7–12.6) 1.0
†
11.3–13.4 (µM) 4.3 (1.1–17.5) 2.5 (0.6–11.8) 4.4 (1.1–16.9) 1.7 (0.4–7.7)
13.4–15.9 (µM) 5.9 (1.5–22.9) 2.8 (0.7–11.0) 3.8 (0.9–15.5) 1.3 (0.5–5.6)
>15.9 (µM) 6.2 (1.6–24.2) 3.9 (1.0–15.5) 1.6 (0.4–6.9) 1.8 (0.5–7.5)
* Odds ratios adjusted for age, sex and cysteine concentration,
†
Reference category.
Table 2: Odds ratio’s for
recurrent venous throm-
bosis for quartiles of
amino acid concen-
trations.
Table 3: Odds ratio’s
(95%CI) for the com-
bination of quartiles of
methionine and homocys-
teine concentrations.
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a matched case-control study in 243 patients with venous throm-
bosis, with an OR of 2.4 (95%CI 1.37–4.20) for methionine le-
vels below the median in a multivariate analysis.
The MTHFR 677C>T mutation also has been associated
with an increased risk on venous thrombosis (2), which is
thought to be due to elevation of homocysteine. We found that
the risk of recurrent venous thrombosis associated with a me-
thionine level below the median is highest in subjects with the
MTHFR 677TT genotype, which in theory could also explain the
association between MTHFR 677TT and venous thrombosis.
Because determinants of methionine levels are poorly
studied, it is difficult to indicate causes underlying low methion-
ine levels. It could be possible that a low plasma methionine level
is the result of a low intake of methionine. Another explanation
could be impaired remethylation of homocysteine to methionine.
In subjects with homocystinuria severe MTHFR deficiency is
often accompanied by low methionine levels (17). However, in
our study we did not find significantly lower methionine levels in
subjects with the MTHFR 677TT genotype, which causes a
mildly reduced enzyme activity and increased thermolability
(18).
The other hypothesis tested in our study was the role of the
thiol-group of homocysteine (3–6). If the thiol-group of homo-
cysteine is involved in thrombogenesis, it might be expected that
cysteine, a sulfhydryl amino acid which is structurally very simi-
lar to homocysteine, is also associated with an increased risk of
thrombosis. We found no dose-response relationship between
cysteine levels and the risk of venous thrombosis after adjust-
ment for age and sex. However, high cysteine levels (top quartile)
were associated with a two-fold increased thrombotic risk after
adjusting for age and sex. With regard to this data we cannot draw
solid conclusions whether cysteine is a risk factor for recurrent
venous thrombosis. We found some other studies that investi-
gated the relationship between elevated cysteine concentrations
and cardiovascular disease (19–26). Only one study reported on
a role of hypercysteinemia in venous thrombosis (20). In that
study, hypercysteinemia [OR=2.9 (95%CI 1.1–7.8)] and hyper-
homocysteinemia [OR=8.0 (95%CI 3.6–18.0)] were both risk
factors for venous thrombosis; however, they did not adjust for
methionine levels.
In conclusion, we found low fasting methionine to be a risk
factor for recurrent venous thrombosis. This risk association was
stronger for methionine than for homocysteine and cysteine.
This observation supports the hypothesis that impaired methyl-
ation may play a role in the development of recurrent venous
thrombosis in hyperhomocysteinemia.
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